Genmab — Maj 2020
-
Fra below 2000 from yesterday.
-
Amerikansk biotekselskab får adgang til Genmabs medicinplatform
Genmab og det amerikanske biotekselskab Tavotek har indgået en forskningsaftale, der skal kombinere de to selskabers platforme til at identificere nye lægemiddelkandidater mod autoimmune og inflammatoriske sygdomme.
(medwatch.dk)
-
nyt samarbejde med Tavotek
-
-
Svært at klage med en stigning på 4,5%
-
they are really keen to promote their epco poster lol https://twitter.com/Genmab/status/1266021659988963328
-
E L - have you found a possibility for private investors to follow the presentation? Or should we as previous years wait for tweets from the oncologists?
-
No they are apparantly prerecorded. There cant be much discussion...
-
Genmab Announces Positive Topline Results in Phase III ANDROMEDA Study of Daratumumab in Light-chain (AL) Amyloidosis
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind